| Year |
Citation |
Score |
| 2016 |
Hanlon KE, Lozano-Ondoua AN, Umaretiya PJ, Symons-Liguori AM, Chandramouli A, Moy JK, Kwass WK, Mantyh PW, Nelson MA, Vanderah TW. Modulation of breast cancer cell viability by a cannabinoid receptor 2 agonist, JWH-015, is calcium dependent. Breast Cancer (Dove Medical Press). 8: 59-71. PMID 27186076 DOI: 10.2147/BCTT.S100393 |
0.56 |
|
| 2013 |
Largent-Milnes TM, Brookshire SW, Skinner DP, Hanlon KE, Giuvelis D, Yamamoto T, Davis P, Campos CR, Nair P, Deekonda S, Bilsky EJ, Porreca F, Hruby VJ, Vanderah TW. Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects. The Journal of Pharmacology and Experimental Therapeutics. 347: 7-19. PMID 23860305 DOI: 10.1124/jpet.113.205245 |
1 |
|
| 2013 |
Lozano-Ondoua AN, Hanlon KE, Symons-Liguori AM, Largent-Milnes TM, Havelin JJ, Ferland HL, Chandramouli A, Owusu-Ankomah M, Nikolich-Zugich T, Bloom AP, Jimenez-Andrade JM, King T, Porreca F, Nelson MA, Mantyh PW, et al. Disease modification of breast cancer-induced bone remodeling by cannabinoid 2 receptor agonists. Journal of Bone and Mineral Research : the Official Journal of the American Society For Bone and Mineral Research. 28: 92-107. PMID 22903605 DOI: 10.1002/jbmr.1732 |
1 |
|
| 2011 |
Hanlon KE, Herman DS, Agnes RS, Largent-Milnes TM, Kumarasinghe IR, Ma SW, Guo W, Lee YS, Ossipov MH, Hruby VJ, Lai J, Porreca F, Vanderah TW. Novel peptide ligands with dual acting pharmacophores designed for the pathophysiology of neuropathic pain. Brain Research. 1395: 1-11. PMID 21550594 DOI: 10.1016/j.brainres.2011.04.024 |
1 |
|
| 2011 |
Lee YS, Kulkarani V, Cowell SM, Ma SW, Davis P, Hanlon KE, Vanderah TW, Lai J, Porreca F, Vardanyan R, Hruby VJ. Development of potent μ and δ opioid agonists with high lipophilicity. Journal of Medicinal Chemistry. 54: 382-6. PMID 21128594 DOI: 10.1021/jm100982d |
1 |
|
| 2010 |
Hanlon KE, Vanderah TW. Constitutive activity at the cannabinoid CB(1) receptor and behavioral responses. Methods in Enzymology. 484: 3-30. PMID 21036224 DOI: 10.1016/B978-0-12-381298-8.00001-0 |
1 |
|
| 2009 |
Hanlon K, Rudin CE, Harries LW. Investigating the targets of MIR-15a and MIR-16-1 in patients with chronic lymphocytic leukemia (CLL). Plos One. 4: e7169. PMID 19779621 DOI: 10.1371/journal.pone.0007169 |
1 |
|
| 2009 |
Hanlon K, Harries LW, Ellard S, Rudin CE. Evaluation of 13q14 status in multiple myeloma by digital single nucleotide polymorphism technology. The Journal of Molecular Diagnostics : Jmd. 11: 450-7. PMID 19644022 DOI: 10.2353/jmoldx.2009.090027 |
1 |
|
| 2009 |
Hanlon K, Ellard S, Rudin CE, Thorne S, Davies T, Harries LW. Evaluation of 13q14 status in patients with chronic lymphocytic leukemia using single nucleotide polymorphism-based techniques. The Journal of Molecular Diagnostics : Jmd. 11: 298-305. PMID 19460942 DOI: 10.2353/jmoldx.2009.080167 |
1 |
|
| 2009 |
Lippert E, Girodon F, Hammond E, Jelinek J, Reading NS, Fehse B, Hanlon K, Hermans M, Richard C, Swierczek S, Ugo V, Carillo S, Harrivel V, Marzac C, Pietra D, et al. Concordance of assays designed for the quantification of JAK2V617F: A multicenter study Haematologica. 94: 38-45. PMID 19001280 DOI: 10.3324/haematol.13486 |
1 |
|
| 2007 |
Wolstencroft EC, Hanlon K, Harries LW, Standen GR, Sternberg A, Ellard S. Development of a quantitative real-time polymerse chain reaction assay for the detection of the JAK2 V617F mutation Journal of Molecular Diagnostics. 9: 42-46. PMID 17251334 DOI: 10.2353/jmoldx.2007.060083 |
1 |
|
| Show low-probability matches. |